Modeling and Simulation of Organophosphate-induced Neurotoxicity: Prediction and Validation by Experimental Studies
Overview
Neurology
Toxicology
Authors
Affiliations
Exposure to organophosphorus (OP) compounds, either pesticides or chemical warfare agents, represents a major health problem. As potent irreversible inhibitors of cholinesterase, OP may induce seizures, as in status epilepticus, and occasionally brain lesions. Although these compounds are extremely toxic agents, the search for novel antidotes remains extremely limited. In silico modeling constitutes a useful tool to identify pharmacological targets and to develop efficient therapeutic strategies. In the present work, we developed a new in silico simulator in order to predict the neurotoxicity of irreversible inhibitors of acetyl- and/or butyrylcholinesterase (ChE) as well as the potential neuroprotection provided by antagonists of cholinergic muscarinic and glutamate N-methyl-d-aspartate (NMDA) receptors. The simulator reproduced firing of CA1 hippocampal neurons triggered by exposure to paraoxon (POX), as found in patch-clamp recordings in in vitro mouse hippocampal slices. In the case of POX intoxication, it predicted a preventing action of the muscarinic receptor antagonist atropine sulfate, as well as a synergistic action with the non-competitive NMDA receptor antagonist memantine. These in silico predictions relative to beneficial effects of atropine sulfate combined with memantine were recapitulated experimentally in an in vivo model of POX in adult male Swiss mice using electroencephalic (EEG) recordings. Thus, our simulator is a new powerful tool to identify protective therapeutic strategies against OP central effects, by screening various combinations of muscarinic and NMDA receptor antagonists.
Li Y, Yang X, Yan S, Sun Z Cogn Neurodyn. 2024; 18(3):1265-1283.
PMID: 38826656 PMC: 11143170. DOI: 10.1007/s11571-023-09958-8.
Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning.
Kuznetsova D, Gaynanova G, Vasilieva E, Pavlov R, Zueva I, Babaev V Pharmaceutics. 2022; 14(9).
PMID: 36145698 PMC: 9506492. DOI: 10.3390/pharmaceutics14091950.
From Qualitative to Quantitative AOP: A Case Study of Neurodegeneration.
Sinitsyn D, Garcia-Reyero N, Watanabe K Front Toxicol. 2022; 4:838729.
PMID: 35434701 PMC: 9006165. DOI: 10.3389/ftox.2022.838729.
Tackling the Molecular Drug Sensitivity in the Sea Louse Based on mRNA and lncRNA Interactions.
Nunez-Acuna G, Saez-Vera C, Valenzuela-Munoz V, Valenzuela-Miranda D, Arriagada G, Gallardo-Escarate C Genes (Basel). 2020; 11(8).
PMID: 32726954 PMC: 7464394. DOI: 10.3390/genes11080857.
Jiang P, Yang X, Sun Z Cogn Neurodyn. 2020; 14(4):483-500.
PMID: 32655712 PMC: 7334339. DOI: 10.1007/s11571-020-09586-6.